SCN3A deficiency associated with increased seizure susceptibility

Tyra Lamar, Emory University
Carlos G. Vanoye, Northwestern University
Jeffrey Calhoun, Northwestern University
Jennifer Wong, Emory University
Stacey B.B. Dutton, Emory University
Benjamin S. Jorge, Vanderbilt University
Milen Velinov, Albert Einstein College of Medicine
Andrew Escayg, Emory University
Jennifer A. Kearney, Northwestern University

Journal Title: Neurobiology of Disease
Volume: Volume 102
Publisher: Elsevier: 12 months | 2017-06-01, Pages 38-48
Type of Work: Article | Post-print: After Peer Review
Publisher DOI: 10.1016/j.nbd.2017.02.006
Permanent URL: https://pid.emory.edu/ark:/25593/sqcg9

Final published version: http://dx.doi.org/10.1016/j.nbd.2017.02.006

Copyright information:
© 2017 Elsevier Inc.

Accessed October 6, 2019 3:24 AM EDT
SCN3A deficiency associated with increased seizure susceptibility

Tyra Lamar1,*, Carlos G. Vanoye2,*, Jeffrey Calhoun2,*, Jennifer C. Wong†, Stacey B.B. Dutton1, Benjamin S. Jorge3, Milen Velinov4, Andrew Escayg1,†, and Jennifer A. Kearney2,†

1Department of Human Genetics, Emory University, Atlanta, Georgia, USA
2Department of Pharmacology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, 60611, USA
3Neuroscience Program, Vanderbilt University, Nashville, Tennessee, 37232, USA
4New York State Institute for Basic Research in Developmental Disabilities, Staten Island, NY, USA Albert Einstein College of Medicine, Bronx, NY, USA

Abstract

Mutations in voltage-gated sodium channels expressed highly in the brain (SCN1A, SCN2A, SCN3A, and SCN8A) are responsible for an increasing number of epilepsy syndromes. In particular, mutations in the SCN3A gene, encoding the pore-forming Na\textsubscript{v}1.3 α subunit, have been identified in patients with focal epilepsy. Biophysical characterization of epilepsy-associated SCN3A variants suggests that both gain- and loss-of-function SCN3A mutations may lead to increased seizure susceptibility. In this report, we identified a novel SCN3A variant (L247P) by whole exome sequencing of a child with focal epilepsy, developmental delay, and autonomic nervous system dysfunction. Voltage clamp analysis showed no detectable sodium current in a heterologous expression system expressing the SCN3A-L247P variant. Furthermore, cell surface biotinylation demonstrated a reduction in the amount of SCN3A-L247P at the cell surface, suggesting the SCN3A-L247P variant is a trafficking-deficient mutant. To further explore the possible clinical consequences of reduced SCN3A activity, we investigated the effect of a hypomorphic Scn3a allele (Scn3a\textsuperscript{Hyp}) on seizure susceptibility and behavior using a gene trap mouse line. Heterozygous Scn3a mutant mice (Scn3a\textsuperscript{+/-Hyp}) did not exhibit spontaneous seizures nor were they susceptible to hyperthermia-induced seizures. However, they displayed increased susceptibility to electroconvulsive (6 Hz) and chemiconvulsive (flurothyl and kainic acid) induced seizures. Scn3a\textsuperscript{+/-Hyp} mice also exhibited deficits in locomotor activity and motor learning. Taken together, these results provide evidence that loss-of-function of SCN3A caused by reduced protein

†Corresponding Authors Andrew Escayg, Ph.D., Department of Human Genetics, Whitehead Biomedical Research Building, 615 Michael Street, Suite 301, Emory University, Atlanta, Georgia, USA 30322, Tel: 404-712-8328, aescayg@emory.edu. Jennifer A. Kearney, Ph.D., Department of Pharmacology, Searle 8-510, 320 East Superior St., Northwestern University, Chicago, IL 60611, Tel: 312-503-4894, jennifer.kearney@northwestern.edu.

*equal contribution

Publisher’s Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
expression or deficient trafficking to the plasma membrane may contribute to increased seizure susceptibility.

Keywords
SCN3A; Na\textsubscript{v}1.3; Focal epilepsy; Voltage-gated sodium channel; seizure susceptibility

1. Introduction
Voltage-gated sodium channels (VGSCs) are responsible for the initiation and propagation of action potentials in excitable cells such as neurons. In the mammalian brain, the most highly expressed VGSC α subunits are SCN1A, SCN2A, SCN3A, and SCN8A, which encode Na\textsubscript{v}1.1, Na\textsubscript{v}1.2, Na\textsubscript{v}1.3, and Na\textsubscript{v}1.6 respectively. Mutations in these VGSCs are responsible for an increasing number of epilepsy syndromes (Escayg et al., 2000; Estacion et al., 2014; Fung et al., 2015; Howell et al., 2015; Schwarz et al., 2016; Sugawara et al., 2001; Surovy et al., 2016). Mutations in SCN1A have been established as the main cause of Dravet syndrome and have also been identified in some families with generalized epilepsy with febrile seizures plus (GEFS+) (Escayg and Goldin, 2010; Scheffer et al., 2009; Volkers et al., 2011). SCN2A mutations have been identified in patients with benign familial neonatal-infantile seizures, and both SCN2A and SCN8A mutations have been identified in some cases of severe epileptic encephalopathies (de Kovel et al., 2014; Estacion et al., 2014; Hackenberg et al., 2014; Heron et al., 2002; Sugawara et al., 2001; Vaheer et al., 2014; Veeramah et al., 2012).

To date, only a few SCN3A mutations have been identified in patients with focal epilepsy. Electrophysiological analysis of these mutations in either transfected rat hippocampal pyramidal neurons (Estacion et al., 2010; Holland et al., 2008) or tsA201 cells (Chen et al., 2015; Vanoye et al., 2014) revealed increased persistent sodium current or elevated ramp currents. In contrast, there is one report of an SCN3A mutation, N302S, identified through a genetic screen of GEFS+ patients, that resulted in depolarizing shifts in voltage-dependent activation and inactivation, as well as slower recovery from slow inactivation, thereby predicting a reduction in channel activity (Chen et al., 2015). These results suggest that both gain- and loss-of-function SCN3A mutations may lead to epilepsy.

Epilepsy syndromes, including those caused by sodium channel mutations, are often accompanied by neuropsychiatric comorbidities, such as anxiety, autism spectrum disorders, and intellectual disability (Baasch et al., 2014; de Kovel et al., 2014; Han et al., 2012). Consistent with this, developmental delay or behavioral abnormalities have been reported in patients with SCN3A mutations. For example, one patient presented with speech delay and attention-deficit/hyperactivity disorder (Vanoye et al., 2014). Another patient was diagnosed with nonverbal learning disability, and the patient carrying the N302S mutation was diagnosed with intellectual disability (Chen et al., 2014; Vanoye et al., 2014).

In this study, we report a novel SCN3A mutation (L247P) associated with childhood focal epilepsy and global developmental delay. Using a combination of electrophysiology and cell surface biotinylation experiments, we demonstrate that SCN3A-L247P encodes a trafficking
deficient channel. To more broadly investigate the possible clinical consequences of reduced SCN3A activity, we characterized the seizure and behavioral phenotypes of the available Scn3a\textsuperscript{Gt(OST52130)Lex} mouse line, which expresses a hypomorphic Scn3a allele (Scn3a\textsuperscript{Hyp}). Heterozygous mutants (Scn3a\textsuperscript{+/-Hyp}) displayed increased susceptibility to induced seizures, but did not exhibit spontaneous seizures. Additionally, Scn3a\textsuperscript{Hyp} mice showed deficits in locomotor activity and motor learning. These observations demonstrate that reduced SCN3A function via reduced trafficking or expression can result in increased seizure susceptibility.

2. Material and Methods

2.1. Clinical presentation

Parental consent for release of de-identified medical information was obtained. An 18 month-old female patient was evaluated due to concerns for global developmental delay, central hypotonia, right-sided renal pelviectasis, and microcephaly. She was the second child of a 39-year-old mother and 50-year-old father, both of whom denied consanguinity. The pregnancy was uncomplicated, amniocentesis was declined, and the child was born at full term. At birth, her weight was 2950 g (10%), her length was 50 cm (20%), and her head circumference was 33 cm (10%). Her Apgar scores were 9 and 9. At two days of age she had an episode of cyanosis, apnea, tonic posturing and bradycardia. EEG recording at that time was normal.

Beginning during the first week of life, two distinct types of episodes were observed, and occasionally coincided. The first type consists of a “scared look” followed by paroxysmal events, which include apnea, eyes rolling back, and limbs stiffening. These episodes occur approximately once a month and were subsequently identified as focal seizures. The second type of episode includes skin flushing and sweating and occurs several times a day for 30-second intervals. This clinical presentation is consistent with Harlequin syndrome, which is characterized by unilateral facial erythema with contralateral pallor that is strikingly demarcated at the midline. Although the color change is limited to the head, it can initiate on one side and shift to the other side within the same episode. This coincides with contralateral pupil dilation and ipsilateral ptosis. Video EEG at 14 months of age revealed right frontal-temporal electrographic seizures compatible with focal epilepsy. Various anticonvulsant medications were tried with limited success. The EEG abnormalities were not associated with the autonomic changes; therefore, it was concluded that the episodes of autonomic dysregulation are not epileptic by nature. The patient also developed progressive microcephaly, although her brain and cervical spine MRIs were normal. A routine cardiology examination, which included EKG, echocardiogram, and Holter monitor, showed no abnormalities. On telemetry, however, several episodes of sinus and junctional bradycardia were noted and thought to correspond with vagal activity and the Harlequin flushing. The child was also diagnosed with global developmental delay. She did not sit without support until 16 months after birth and was still unable to walk on her last evaluation at two years of age. Her speech development was also delayed. Additionally, her height, weight and head circumference were below the third percentile for two year olds. She also had trunkal hypotonia and mid-face hypoplasia.
Metabolic screening was negative. Familial Dysautonomia was ruled out by observation of normal fungiform tongue papillae and normal axon flare on intradermal histamine testing. Chromosomal microarray analysis was normal. Clinical whole-exome sequencing revealed a single, novel, de novo heterozygous sequence change in the gene SCN3A, L247P. In silico analysis concluded that this change was “likely pathogenic”. Other changes reported were deemed as “benign” or were rare population variants inherited from an unaffected parent, suggesting they were not pathogenic (Supplemental Table 1). Results were confirmed by Sanger sequencing.

2.2. Plasmids and Cell Transfection

Electrophysiology and biochemistry experiments were conducted using tsA201 cells (HEK-293 stably transfected with SV40 large T antigen) grown at 37°C with 5% CO₂ in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum, 2 mM L-glutamine, and penicillin (50 U/ml)-streptomycin (50 μg/ml). Only cells from passage number < 13 were used. A plasmid encoding the major splice isoform of the human SCN3A with exon 5 adult (5A) and exon 12v1 (646 bp) splice variants was used (Wang et al., 2010). Full-length Naᵢ,1.3 was propagated in STBL2 cells at 30°C (Invitrogen), and the open reading frame of all plasmid preparations was fully sequenced prior to transfection. The L247P variant was introduced by site-directed mutagenesis. Plasmids encoding the human Naᵢ channel accessory subunits β₁ or β₂ in vectors containing the marker genes CD8 (pCD8-IRES-β₁) or GFP (pGFP-IRES-β₂) were also used.

For electrophysiology experiments, expression of Naᵢ,1.3, β₁, and β₂ subunits was achieved by transient transfection (2 μg of total cDNA: SCN3A, β₁, β₂ mass ratio was 10:1:1) using Superfect Transfection Reagent (QIAGEN, Valencia, CA, USA). Cells were incubated as described above for 48 hours after transfection before use in electrophysiology experiments. For low temperature rescue experiments, cells were incubated for 24 hours at 37°C followed by 24 hours at 28°C prior to electrophysiology. Transfected cells were dissociated by brief exposure to trypsin/EDTA, resuspended in supplemented DMEM medium, plated on glass coverslips, and allowed to recover for ~2 hrs at 37°C or 28°C in 5% CO₂. Polystyrene microbeads pre-coated with anti-CD8 antibody (Dynabeads M-450 CD 8, Dynal, Great Neck, NY, USA) were added and only cells positive for both CD8 antigen (i.e., β₁ expression) and GFP fluorescence (i.e., β₂ expression) were studied.

For cell surface biotinylation experiments, expression of Naᵢ,1.3, β₁ and β₂ subunits was achieved by transient transfection (2 μg of total cDNA: SCN3A, β₁, β₂ mass ratio was 10:1:1) using Lipofectamine 2000 (Life Technologies, Grand Island, NY, USA). Before use in these experiments, cells were incubated as described above for 48 hours after transfection.

2.3. Electrophysiology

Coverslips were placed into a recording chamber on the stage of an inverted epifluorescence microscope (IX 50, Olympus, Center Valley, PA, USA) and allowed to equilibrate for 10 min in bath solution prior to starting experiments. Bath solution contained (in mM): 145 NaCl, 4 KCl, 1.8 CaCl₂, 1 MgCl₂, 2 HEPES (N-(2-hydroxyethyl) piperazine-N’-2-ethansulphonic acid), pH 7.35, 310 mOsm/kg. The composition of the pipette solution was (in mM): 10
NaF, 110 CsF, 20 CsCl, 2 EGTA (ethyleneglycol-bis-(β-aminoethylether), 10 HEPES, pH 7.35, 310 mOsm/kg. Osmolarity and pH values were adjusted with sucrose and NaOH, respectively. A 2% agar-bridge with composition similar to the bath solution was utilized as a reference electrode. Junction potentials were zeroed with the filled pipette in the bath solution. Unless otherwise stated, chemicals were obtained from Sigma-Aldrich (St. Louis, MO, USA).

Patch pipettes were pulled from thin-wall borosilicate glass (World Precision Instruments, Inc., Sarasota, FL, USA) using a multistage P-97 Flaming-Brown micropipette puller (Sutter Instruments Co., San Rafael, CA, USA) and fire-polished with a Micro Forge MF 830 (Narashige, Japan). After heat polishing, the resistance of the patch pipettes was 1–3 MΩ in standard bath and pipette solutions. Once whole-cell recording mode was achieved, the access resistance averaged 2.5 ± 0.1 MΩ. Whole-cell sodium currents were recorded as previously described (Lossin et al., 2002; Vanoye et al., 2006) at room temperature (20–23°C) in the whole-cell configuration of the patch-clamp technique (Hamill et al., 1981) using an Axopatch 200B series amplifier (Molecular Devices Corp, Sunnyvale, CA, USA). Cells were allowed to equilibrate for 10 min after establishment of the whole-cell configuration before currents were recorded. Pulse generation was performed with Clampex 8.1 (Molecular Devices Corp.) and whole-cell currents were acquired at 20 kHz and filtered at 5 kHz. Linear leak and residual capacitance artifacts were subtracted out using the P/4 method. To reduce voltage errors, 80–90% series resistance and prediction compensation were applied. Cells were excluded from analysis if the predicted voltage error exceeded 3 mV or the current at the holding potential (−120 mV) was >5% of the peak current.

Peak currents were measured using 20 ms pulses between −80 and +50 mV every 5 s from a holding potential of −120 mV. The peak current was normalized for cell capacitance and plotted against voltage to generate peak current density–voltage relationships.

Data were collected from at least 2 transient transfections per experimental condition. Results are reported as means ± SEM, and number of cells used for each experimental condition are listed on the legends or figures. Current values were normalized to membrane capacitance.

2.4. Cell Surface Biotinylation

Forty-eight hours post-transfection, cell surface proteins of transfected tsA201 cells were labeled with cell membrane impermeable Sulfo-NHS-Biotin (Thermo Scientific, Waltham, MA, USA). The biotinylation reaction was quenched with 100mM glycine, and the cells were subsequently lysed with RIPA lysis buffer (Thermo Scientific) containing Complete protease inhibitors (Roche Applied Science, Indianapolis, IN, USA) and clarified by centrifugation. An aliquot of the supernatant was retained as the total protein fraction. Biotinylated surface proteins (300 to 600 μg per sample) were recovered from the remaining supernatant by incubation with streptavidin-agarose beads (Thermo Scientific) and elution in Laemmli sample buffer. Total (5 to 10 μg per lane) and surface fractions were analyzed by Western blotting using rabbit anti-pan VGSC α. subunit (1:250; Alomone, Jerusalem, Israel), mouse anti-transferrin receptor (1:500; Life Technologies), and rabbit anti-calnexin (H70) (1:250; Santa Cruz Biotechnology, Dallas, TX, USA) primary antibodies. Peroxidase-
conjugated mouse anti-rabbit immunoglobulin G (IgG; 1:20,000; Jackson ImmunoResearch, West Grove, PA, USA) and goat anti-mouse IgG (1:40,000, Jackson ImmunoResearch) secondary antibodies were utilized. Blots were probed for each protein in succession, stripping in between with Restore Western Blot Stripping Buffer (Pierce Biotechnology, Rockford, IL, USA). Calnexin immunoreactivity was present in total protein lysates and absent from cell surface fraction, confirming the selectivity of biotin labeling for cell surface proteins. Densitometry was performed using NIH ImageJ software. Transferrin receptor was utilized as a loading control for Na\(_{v}\)1.3 immunoreactive bands. Surface fractions were analyzed from two independent transfections, while total fractions were analyzed from three independent transfections.

2.5. Mouse Model

The Scn3a\(^{Gt(OST52130)Lex}\) mouse line (Lexicon Pharmaceuticals Inc.), containing a gene trap vector upstream of the first coding exon, was purchased from the Mutant Mouse Regional Resource Center (University of North Carolina at Chapel Hill, NC, USA). The line was maintained by backcrossing to C57BL/6J mice (Jackson Laboratories, Bar Harbor, ME, US). RNA and protein analysis in adult mice as well as all seizure and behavioral experiments were performed on heterozygous mutants and WT littermates generated by crossing N6-N7 Scn3a\(^{+/Hyp}\) males to C57BL/6J females. WT, heterozygous, and homozygous littermates (P1) that were used for RNA and protein analysis were generated by mating heterozygous siblings from the N8-N9 generations. Mice were housed in an animal facility with a 12-hour light/dark cycle (lights on 7:00am – lights off 7:00pm) with food and water available ad libitum. All experiments were performed in accordance with the guidelines of the Emory University Institutional Animal Care and Use Committees. Unless stated otherwise, adult (4–6 month old) mice were used for the following experiments.

2.6. Genotyping

Genotyping was performed on DNA extracted from tail biopsies. To detect the wild-type allele, forward and reverse PCR primers were designed in the intronic sequences flanking the vector insertion site (3AF: GAGGATCAGGCTTAGCGGTG; 3AR: TCTGGTCTGTTATGTCAGAAGGC) to produce a 337 bp PCR product. To detect the mutant allele, a forward primer was designed in the vector sequence (VECTF: TATGTATTTTTCCATGCCTTGC) and paired with the 3AR reverse primer to produce a 233 bp PCR product.

2.7. Quantitative real-time PCR (qRT-PCR)

Total RNA was extracted from whole brain samples of 1-day old (P1) homozygous (Scn3a\(^{Hyp/Hyp}\); n = 3) and heterozygous (Scn3a\(^{+/Hyp}\); n = 5) mutants and wild-type (WT; n = 4) littermates. RNA extraction and cDNA synthesis were performed as previously described (Makinson et al., 2014). PCR amplification of Scn1a, Scn2a, Scn3a and Scn8a was performed using primers designed to span two exons. The following primer pairs were used: Scn1a (F: CAGGAGGAAGGGTTTCGCTTC, R: CCCCACATCCTGGGTCGCCCTC), Scn2a (F: CTGCAACGGTGTGGTCTCCCTAG, R: ATGTAGGGTCTTCCAACAGTCC), Scn3a (F: CCTGGACCCCTACTACGTCA, R: TGTGTACTCTACATTCTCCGTCCA), and Scn8a (F: AGATTTAGCGCCACTCTGC, R: GGACCATTCCGGAGGGTTAC). Each
primer pair produced standard curves with 90–100% efficiency. Real-time analysis was performed in technical triplicate using the BioRad CFX96 Real-Time PCR Detection System and SYBR Green fluorescent dye (BioRad, Hercules, CA, USA). Expression levels were normalized to beta-actin (F: CAGCTTCTTTGCAGCTCTT, R: ACGATGGAGGGAATAACAGC). Expression relative to WT was determined using the Pfaffl calculation (Pfaffl, 2001).

2.8. Western Blot Analysis

Whole brains were extracted from P1 WT (n = 5), Scn3a+/Hyp (n = 6), and Scn3aHyp/Hyp littermates (n = 4). Tissue was homogenized with a Dounce homogenizer in cold protease inhibitor buffer (50mM Tris, pH 7.5; 10mM EGTA; 1 protease inhibitor cocktail tablet (Roche) per 50mL of buffer). The homogenate solution was centrifuged at 3500 RPM for 10 minutes at 4°C. The resulting supernatant was centrifuged at 38,000 RPM for 30 minutes at 4°C. The membrane-enriched pellet was resuspended in protease inhibitor buffer and then stored at −80°C. Protein was quantified using the BCA protein assay (Pierce, Rockford, IL, USA). The protein (50 μg) was then denatured, separated by SDS-PAGE, and transferred to PVDF membrane. The membranes were blocked with 5% milk, then incubated at 4°C overnight with either polyclonal rabbit anti-Na\textsubscript{v}1.1 (1:200; Millipore, Billerica, MA), Na\textsubscript{v}1.2 (1:200; Millipore), Nav1.3 (1:200; Alomone), or Na\textsubscript{v}1.6 (1:200; Millipore), followed by HRP-conjugated donkey anti-rabbit secondary antibody (1:3000; GE Healthcare Life Sciences, Little Chalfont, UK) for 1 hour. To normalize for variation in protein loading, membrane blots were also incubated for 1 hour with monoclonal mouse anti-tubulin (1:5000; Sigma-Aldrich) followed by HRP-conjugated goat anti-mouse secondary antibody (1:3000; Jackson ImmunoResearch). Following each secondary antibody, all blots were incubated in HyGlo Quick Spray (Denville Scientific, Holliston, MA, USA) and imaged. Protein expression was quantified using Image J software (NIH).

2.9. Hyperthermia-induced Seizures

Susceptibility to hyperthermia-induced seizures in P21–22 Scn3a+/Hyp mutants (n = 12) and WT littermates (n = 13) was determined as previously described (Dutton et al., 2013). Since mice are not sexually mature at this age, results from male and female mice were combined. Briefly, the body temperature of each mouse was monitored and controlled via a rectal temperature probe that was connected to a heating lamp and temperature controller (TCAT 2DF, Physitemp, Clifton, NJ, USA). Each mouse was placed in a clear cylinder and held at 37.5°C for 10 minutes. The core body temperature of each mouse was then increased by 0.5°C every two minutes until either a seizure occurred or a temperature of 42.5°C was reached. The temperature at which each mouse exhibited a GTCS was compared between genotypes. Behavioral seizures were also scored using a modified Racine scale (Racine, 1972): 1 – staring, 2 – head nodding, 3 – unilateral forelimb clonus, 4 – bilateral forelimb clonus, 5 – rearing and falling, 6 – generalized tonic-clonic seizure (GTCS).

2.10. 6 Hz Seizure Induction

The topical anesthetic tetracaine (0.5%, Bausch and Lomb, Rochester, NY, USA) was applied to each eye 30 minutes prior to seizure induction. Adult male Scn3a+/Hyp mutants and WT littermates (n = 10/genotype) were subjected to 6 Hz corneal stimulation (0.2 ms
pulse width, 3 s duration) using an ECT unit (Ugo Basile; Comerio, Italy). Each mouse was tested once per week, over a 3-week period, using a current of 16, 24, or 30 mA. Behavioral seizures were scored using a modified Racine scale: 0 – no seizure, 1 – staring, 2 – forelimb clonus, and 3 – rearing and falling. For each genotype, the CC$_{50}$ (the convulsive current at which 50% of mice seize) was established as well as the average Racine scores at each current.

2.11. Flurothyl Seizure Induction

Seizure induction using flurothyl (2,2,2-trifluoroethyl ether, Sigma-Aldrich) was performed as previously described (Makinson et al., 2014; Martin et al., 2007; Sawyer et al., 2014). Briefly, 5–8 week old Scn3a$^{+/\text{Hyp}}$ male and female mutants ($n = 29$/sex) and WT littermates (male $n = 33$; female $n = 32$) were placed in a clear chamber and flurothyl was introduced at a constant rate of 20 μl/min. Latencies to the first myoclonic jerk, first generalized tonic-clonic seizure (GTCS) with loss of posture, and hind limb extension were recorded.

2.12. EEG cortical/depth electrode surgery

Electroencephalogram (EEG) electrodes were surgically implanted in adult male Scn3a$^{+/\text{Hyp}}$ mice ($n = 6$) and WT littermates ($n = 4$) as previously described (Dutton et al., 2013; Makinson et al., 2014; Martin et al., 2007; Papale et al., 2013). Briefly, two pairs of bipolar stainless steel screw electrodes (Vintage Machine Supplies, OH, USA) were implanted in the skull at the following coordinates (relative to bregma): anterior-poster (AP) +0.5 mm and medial-lateral (ML) −2.2 mm; AP +2.0 mm and ML +1.2 mm; AP −3.5 mm and ML −2.2 mm; AP −1.5 mm and ML +1.2 mm. Two fine-wire electrodes were implanted in the dorsal neck muscles to record electromyography (EMG) activity.

Depth EEG recordings were obtained in adult male Scn3a$^{+/\text{Hyp}}$ mice ($n = 3$) and WT littermates ($n = 2$). Two depth electrodes were implanted into the hippocampus (relative to bregma): AP −1.8 mm, ML ±1.6 mm, dorsal-ventral (DV) −1.7 mm. Two cortical electrodes were also implanted (relative to bregma): AP +2.0 mm and ML+1.2 mm; AP +0.5 mm and ML −2.2 mm. EMG electrodes were not implanted for depth EEG recordings.

For all surgeries, mice were administered Meloxicam (2 mg/kg; Norbrook Laboratories, Lenexa, KS, USA) preoperatively and postoperatively for two days following surgery (1 mg/kg). Each mouse was allowed to recover from surgery for at least 7 days before the onset of EEG recording. Twelve days of continuous video/EEG recording were collected from each mouse, and EEG signals were analyzed with Stellate Harmonie EEG software (Natus Medical Inc., San Carlos, CA, USA) using a high-pass filter of 0.5 Hz and a low-pass filter of 35 Hz. For the cortical-only recordings, EMG signals were analyzed using a high-pass filter of 10 Hz and a low-pass filter of 70 Hz. Two montages were used to manually score the cortical-only and depth EEG recordings. In the first montage, one muscle electrode was used as the reference. Since muscle electrodes were not implanted during the depth electrode surgery, the second montage used a cortical electrode as a reference. Seizure activity was defined as synchronous discharges of increasing frequency with amplitudes at least twice the background.
2.13. Kainic Acid Seizure Induction

Male Scn3a<sup>-/-</sup>Hyp mutants (n = 8) and WT littermates (n = 5) were administered kainic acid (i.p., 20 mg/kg, Sigma-Aldrich) and observed for two hours. Seizures were confirmed by EEG analysis using cortical electrode and hippocampal depth electrodes as described above. Behavioral seizures were scored using a modified Racine scale: 0 – no behavior, 1 – freezing/staring, 2 – head nodding, 3 – tail clonus, 4 – forelimb clonus, 5 – rearing and falling, and 6 – death (Makinson et al., 2014; Martin et al., 2007; Tang et al., 2009). The latency to the first electrographic seizure in each mouse as well as the average seizure severity during the observation period were compared.

2.14. Locomotor Activity

Adult male Scn3a<sup>-/-</sup>Hyp mice and WT littermates (n= 8/genotype) were placed in novel transparent cages (40 × 20 × 20 cm) equipped with 7 infrared photobeams, each beam spaced 5 cm apart and 5 cm from the cage wall (San Diego Instruments Inc., San Diego, CA, USA). Activity was monitored for 48 hours, and ambulation was recorded as the number of consecutive beam breaks during the time period.

2.15. Rotarod

Adult male Scn3a<sup>-/-</sup>Hyp mice (n =11) and WT littermates (n= 9) were trained on a fixed speed (5 RPM) rotating rod (AccuScan Instruments, Columbus, OH, USA) daily for five minutes across two days. Experimental trials were performed on an accelerating (acceleration: 4–40 RPM) rotarod (Columbus Instruments, Columbus, OH, USA) for three days following training. Animals were subjected to three 5-minute trials each day, with a rest period of 30 minutes between each trial. The latency to fall was recorded for each trial.

2.16. Statistical Analysis

Data was analyzed using the following software: Clampfit 8.1 (Molecular Devices Corp.), Excel 2002 (Microsoft, Seattle, WA, USA), SigmaPlot 10 (Systat Software, Inc., San Jose, CA, USA), Prism 5–6 (GraphPad Software, Inc., La Jolla, CA, USA), and SPSS Statistical Software (IBM, Armonk, NY, USA). mRNA expression (normalized to β-actin), protein expression (normalized to α-tubulin and reported in optical density units), latencies to flurothyl-induced seizures, and latencies to the first KA-induced electrographic seizure were analyzed with a two-tailed Student’s t-test when comparing two genotypes or one-way Analysis of Variance (ANOVA) followed by the Tukey pairwise post hoc comparison when comparing three genotypes. The log-rank (Mantel-Cox) test was used to analyze the number of animals that seized in the hyperthermia-induced seizure paradigm and the temperature at which each mouse seized per genotype. The 6 Hz CC<sub>50</sub> and respective confidence intervals were determined for each genotype using log-probit analysis. Racine scores at each current in the 6 Hz paradigm were analyzed using the nonparametric Mann-Whitney Rank Sum test. A two-way repeated measures ANOVA followed by Bonferroni’s multiple comparisons post hoc analyses was used to analyze the time course of KA-induced seizure severity, the number of ambulations during locomotor activity, and latency to fall during the rotarod task. All bar graphs indicate the means, and all error bars represent ± standard error of the mean (SEM).
3. Results

3.1. The SCN3A-L247P variant is associated with childhood epilepsy and encodes a trafficking deficient channel

Clinical whole-exome sequencing identified a single de novo variant, SCN3A-L247P, in an 18 month-old female patient exhibiting focal seizures, global developmental delay, and autonomic dysfunction. This non-synonymous variant was not present in either parent, or in publically available exome databases (Exome Aggregation Consortium (ExAC), 2016; Exome Variant Server, 2016). SCN3A is highly intolerant of variation with genic intolerance score of −2.48 for missense variants, putting it amongst the top 1% most intolerant of genes (Petrovski et al., 2013). The SCN3A-L247P variant resulted in a non-conservative amino acid substitution at the cytoplasmic face of the S5 transmembrane segment in domain 1 (Fig. 1A and 1B). We attempted to functionally characterize this variant using recombinant human Na\textsubscript{v}1.3 co-expressed with human β1 and β2 subunits in a heterologous expression system (tsA201 cells). However, SCN3A-L247P mutant channels failed to exhibit significant sodium current (Fig. 1C–D). Incubation at low temperature (28°C) for 24 hours did not rescue any significant sodium current (Fig. 1D). Two independent recombinant Na\textsubscript{v}1.3 clones expressing the L247P mutation were tested. The open reading frame of both clones was fully sequenced to rule out cloning artifacts.

The absence of detectable sodium current in cells transfected with SCN3A-L247P suggests that either the mutation affected the level of channel protein at the cell surface, or the mutant channel is expressed at the cell surface but does not conduct sodium. To determine the level of cell surface expression of SCN3A-L247P, we performed cell surface biotinylation (Fig. 1E). There was a significant reduction in the amount of SCN3A-L247P at the level of the cell surface relative to SCN3A-WT (normalized surface VGSC expression = 1.0 for SCN3A-WT and 0.18 for SCN3A-L247P; n = 2). There was also a trend toward a decrease in total cellular SCN3A expression between SCN3A-WT and SCN3A-L247P (normalized total VGSC expression = 1.0 for SCN3A-WT and 0.66 for SCN3A-L247P; p = 0.11, Student’s t-test; n = 3). Fewer Na\textsubscript{v}1.3 channels at the cell surface would be predicted to reduce the magnitude of the inward current, which may contribute to disease pathogenesis.

3.2. Scn3a mRNA and protein expression is reduced in Scn3a\textsuperscript{+/Hyp} and Scn3a\textsuperscript{Hyp/Hyp} mice

To better understand the contribution of SCN3A to disease, we evaluated the Scn3a gene trap mouse line, Scn3a\textsuperscript{Gt(OST52130)Lex}, developed by Lexicon Pharmaceuticals. The original description of this mouse line reported the observation of only two homozygotes from 63 pups at the F2 generation (WT: 20, heterozygous: 41, homozygous: 2; Chi-squared: 16.016, df = 2, p < 0.001), neither of which survived beyond four weeks of age (http://www.informatics.jax.org/external/ko/lexicon/1392.html; Lexicon personal communication).

We generated WT, heterozygous, and homozygous pups for our study by mating heterozygous siblings that had been backcrossed 8–9 generations onto the C57BL/6J strain. Although fewer homozygotes were born than WT pups, we did not observe statistically significant deviations from Mendelian ratios in animals born (WT: 21, heterozygous: 36, homozygous: 10; Chi-squared: 3.985, df = 2, p = 0.14). However, in order to appropriately model the heterozygous SCN3A mutation observed in the patient, we used heterozygous
mutants and WT littermates, generated from crossing male heterozygous mutants to female C57BL/6J mice, for all behavioral experiments. Gross brain morphology of adult heterozygous mutants was normal except for focal cortical anomalies, including disruptions in cortical lamination and invaginations (Supplemental figure 1). These were observed in the majority of Scn3a+/Hyp mice examined, but not in WT littermates. However, cortical malformations have been reported to occur in WT C57BL/6J mice at a low level (Ramos et al., 2008). To confirm disruption of Scn3a in mutant mice, quantitative real-time PCR analysis was performed on whole brain samples from one-day old (P1) WT, heterozygous and homozygous littermates. We observed approximately 70% and nearly 100% reduction of Scn3a mRNA expression (relative to WT) in the brains of P1 heterozygous and homozygous mutants, respectively (p < 0.0001, Fig. 2A). Western blotting indicated that Na\textsubscript{v}1.3 protein expression in the brains of P1 heterozygous and homozygous mutants, compared to WT, was reduced by approximately 35% (p < 0.05) and 60% (p < 0.001), respectively (Fig. 2B). These observations indicate that the Scn3a gene trap allele is hypomorphic (defined henceforth as Scn3a\textsuperscript{Hyp}). In adult heterozygous Scn3a\textsuperscript{+/Hyp} mice, Scn3a mRNA expression was reduced by approximately 60% compared to WT in both the hippocampus and cerebellum (p < 0.05; Supplemental Fig. 2A). Na\textsubscript{v}1.3 protein expression was undetectable in the brains of adult WT and Scn3a\textsuperscript{+/Hyp} mice.

To determine whether Scn3a deficiency could alter the expression levels of other CNS VGSCs, we compared Scn1a, Scn2a, and Scn8a mRNA and protein levels from the brains of Scn3a\textsuperscript{Hyp} mutant mice and WT littermates. Although Scn1a (Fig. 3A), Scn2a (Fig. 3B), and Scn8a (Fig. 3C) mRNA levels were comparable between P1 Scn3a\textsuperscript{+/Hyp} pups and WT littermates, they were significantly reduced in Scn3a\textsuperscript{Hyp/Hyp} pups (p < 0.05). No significant differences in mRNA expression of Scn1a, Scn2a, and Scn8a were observed between adult Scn3a\textsuperscript{+/Hyp} mice and WT littermates (Supplemental Fig. 2B–D). Na\textsubscript{v}1.1, Na\textsubscript{v}1.2, and Na\textsubscript{v}1.6 protein expression was undetectable by Western blotting for all genotypes of P1 mice (data not shown). No significant differences in protein levels of Na\textsubscript{v}1.1, Na\textsubscript{v}1.2 and Na\textsubscript{v}1.6 were observed in adult Scn3a\textsuperscript{+/Hyp} mutant mice compared with WT littermates (Supplemental Fig. 2B–D).

### 3.3. Scn3a\textsuperscript{+/Hyp} mice exhibit increased seizure susceptibility

We first determined whether reduced Scn3a expression increases susceptibility to hyperthermia-induced seizures. Core body temperature of P21–P22 Scn3a\textsuperscript{+/Hyp} mutants and WT littermates was increased by 0.5°C every two minutes until either a generalized tonic-clonic seizure (GTCS) was observed or 42.5°C is reached. No statistically significant differences were observed in the number of mice exhibiting seizures, the temperature at which the seizure occurred, nor the seizure severity between Scn3a\textsuperscript{+/Hyp} mice and WT littermates (Fig. 4).

Next, we assessed the susceptibility of male Scn3a\textsuperscript{+/Hyp} mutants to focal seizures using the 6 Hz “psychomotor” seizure induction paradigm (Brown et al., 1953; Toman, 1951). Male Scn3a\textsuperscript{+/Hyp} mutants and WT littermates were tested at current intensities of 16 mA, 24 mA, and 30 mA. Seizure incidence and severity (based on a modified Racine score, denoted RS) was compared between Scn3a\textsuperscript{+/Hyp} mutants and WT littermates at each current (Fig. 5).
Both genotypes displayed minimal seizure response at 16 mA. However, at 24 mA, 50% (5/10) of Scn3a+/-Hyp mutants seized (3RS1, 2RS2), compared with 10% (1/10) of WT (1RS3). At 30 mA, 90% (9/10) Scn3a+/-Hyp mutants seized (4RS1, 3RS2, 2RS3) compared with 56% (5/9) of WT littermates (1RS1, 1RS2, 3RS3). Based on these results, the CC50 was found to be significantly lower in the Scn3a+/-Hyp mutants [CC50 = 24 mA; 95% CI: 19.8 to 25.4] when compared with WT littermates [CC50 = 29 mA; 95% CI: 26.7 to 38.4] (Fig. 5A). No statistically significant differences were observed in seizure severity between mutant and WT littermates at the currents tested (Fig. 5B).

Latencies to flurothyl-induced seizures were examined in both sexes of Scn3a+/-Hyp mutants and WT littermates (Fig. 6). The average latency to the first myoclonic jerk was reduced in Scn3a+/-Hyp mutants compared to WT littermates in both sexes. Average latencies to the first GTCS were comparable between male Scn3a+/-Hyp mutant and male WT littermates (Fig. 6A); however, female Scn3a+/-Hyp mutants exhibited significantly reduced latencies to the GTCS when compared to female WT littermates (p < 0.01, Fig. 6B). In both sexes, Scn3a+/-Hyp mice progressed to hindlimb extension significantly faster than WT littermates (male: p < 0.001; female: p < 0.001).

The response of male Scn3a+/-Hyp mutants and WT littermates to kainic acid (KA)-induced seizures was also compared (Fig. 7). Scn3a+/-Hyp mutants exhibited significantly higher average Racine scores compared to WT littermates from 20 minutes to 2 hours following KA administration (p < 0.05, Fig. 7A). The latency to the first observed electrographic seizure was also significantly reduced in Scn3a+/-Hyp mice (p < 0.05, Fig. 7B). An example of an EEG-confirmed KA-induced seizure in a Scn3a+/-Hyp mutant is shown in Fig. 7C.

### 3.4. Scn3a+/-Hyp mutants do not exhibit spontaneous seizures

Male Scn3a+/-Hyp mutants (n= 6) and WT littermates (n= 4) were implanted with cortical electrodes and continuous video/EEG analysis was performed for 12 days (288 hours each mouse). No spontaneous seizures were detected during the recording period. Since patients with SCN3A mutations exhibit focal seizures, we also performed EEG analysis on Scn3a+/-Hyp mice (n= 3) and WT littermates (n = 2) using depth electrodes positioned bilaterally in the dorsal hippocampus. Each mouse was continuously monitored by video/EEG analysis for 12 days; however, no spontaneous seizures were detected.

### 3.5. Scn3a+/-Hyp mutants are hypoactive and display deficits in motor learning

The locomotor activity of male Scn3a+/-Hyp mice and WT littermates was continuously monitored for 48 hours and the number of ambulations were recorded (Fig. 8A). Scn3a+/-Hyp mutants traveled significantly less than WT littermates during the first dark cycle (8:00–11:00 pm; hours 6.5 to 9.5) and during the second dark cycle (9:00 – 9:30 pm; hours 31.5–32.0) (p < 0.05, Fig. 8A). We also compared motor learning between Scn3a+/-Hyp mice and WT littermates using an accelerating rotarod. All mice underwent three trials per day for three days. There were no differences in average latencies to fall between the genotypes during the first five trials. During the remaining trials, however, Scn3a+/-Hyp mutants fell from the accelerating rotarod significantly faster than WT littermates (Fig. 8B). A battery of behavioral tests was also conducted on the Scn3a+/-Hyp mutants and WT littermates to
evaluate exploratory activity, anxiety, memory, social behavior, depressive-like behavior, vision, and sensorimotor gating (Supplemental Table 2). No statistically significant differences were observed between mutants and WT littermates in any of these behavioral tasks, with the exception of the open field in which Scn3a<sup>Hyp</sup> mice entered the center zone significantly fewer times when compared to WT littermates (p < 0.05).

4. Discussion

4.1. A novel SCN3A variant (L247P) is associated with childhood epilepsy and displays reduced trafficking to the cell surface

Clinical whole-exome sequencing identified a novel, non-synonymous missense variant in the SCN3A gene, encoding the Na<sub>1.3</sub> VGSC α subunit, in a female patient with childhood epilepsy, global developmental delay, and autonomic nervous system dysfunction. The L247P substitution replaces a highly conserved leucine residue with proline at the cytoplasmic face of the DIS5 transmembrane domain (Fig. 1B). This substitution is predicted to affect the secondary structure of SCN3A, which could alter the function or trafficking of the channel (Supplemental Table 1). We demonstrate herein that SCN3A-L247P is a trafficking deficient mutant. This finding provides further support for loss-of-function of SCN3A as a pathogenic mechanism.

There is a precedent for the rescue of trafficking-deficient sodium channel mutants by co-expression of VGSC β subunits, other interacting proteins, or pharmacologic agents (Bechi et al., 2015; Cestele et al., 2013; Rusconi et al., 2009; Rusconi et al., 2007; Thompson et al., 2012). The biochemical and functional assays of SCN3A-L247P were performed in cells co-transfected with β1 and β2 subunits, suggesting that β1 and β2 are not sufficient to rescue the trafficking of SCN3A-L247P. Further experimentation will be necessary to ascertain whether the trafficking of SCN3A-L247P can be rescued by other interacting proteins or pharmacologic agents.

4.2. In vivo characterization of Scn3a haploinsufficiency

In order to further explore the potential of reduced SCN3A activity to confer elevated seizure risk in vivo, we studied the gene trapped Scn3a<sup>Gt(OST52130)Lex</sup> line. Scn3a mRNA expression in P1 mice was found to be significantly reduced in heterozygous mutants, and Na<sub>1.3</sub> protein levels were approximately 35% lower than in WT littermates. Interestingly, although Scn3a mRNA in homozygous mutants was almost undetectable, Na<sub>1.3</sub> protein was still detected, indicating that this mouse line is hypomorphic. It is well recognized that mRNA and protein expression levels do not always correlate due to experimental noise, the stability of the RNA or protein, or modifications at the transcriptional or translational level (Maier et al., 2009; Nie et al., 2006; Raj et al., 2006). We were unable to detect Na<sub>1.3</sub> protein in the adult WT mouse brain by Western blot, which is consistent with observations from a previous study (Cheah et al., 2013). The lack of detectable Na<sub>1.3</sub> protein in adult brain also confirmed the specificity of the Scn3a antibody, since we showed that all other CNS VGSCs are detectable in the adult brain.
Previous observations by Lexicon indicated reduced viability of homozygous Scn3a^{Hyp/Hyp} mutants, suggesting that Scn3a is critical during early development. In the current study, we did not observe significant skewing of Mendelian ratios when the three genotypes (WT, Scn3a^{+/Hyp}, Scn3a^{Hyp/Hyp}) were examined at P1. However, Lexicon observations were based on numbers at the time of genotyping (P10 at earliest); therefore, homozygous mutants likely exhibit postnatal lethality. We also investigated whether the expression of the other brain VGSCs would be altered due to the reduced expression of Scn3a. Previous studies have demonstrated that sodium channel deficiency can result in changes in expression of other VGSCs. For example, Scn1b-null mice exhibit reduced Na_v1.1 and increased Na_v1.3 protein levels (Chen et al., 2004). Analysis of Scn1a knockout mice also showed compensatory upregulation of Na_v1.3 in hippocampal interneurons, although this increase was insufficient to restore normal levels of sodium current (Yu et al., 2006). In the current study, Scn1a, Scn2a, and Scn8a mRNA levels were unchanged in P1 Scn3a^{+/Hyp} mice, while mRNA expression was significantly reduced in homozygous mutants. However, since Na_v1.1, Na_v1.2, and Na_v1.6 proteins are undetectable by Western blot in P1 mice, further investigation will be required to determine whether these observed reductions in mRNA levels are functionally important.

To date, only two reported patients with SCN3A mutations (M1323V, N302S) have presented with febrile seizures, suggesting that this is not a common seizure type for SCN3A mutations (Chen et al., 2015; Vanoye et al., 2014). Consistent with clinical observations, Scn3a^{Hyp/Hyp} mice did not show increased susceptibility to hyperthermia-induced seizures. However, Scn3a^{+/Hyp} mice did exhibit increased susceptibility to flurothyl, KA, and 6 Hz-induced seizures. The results from the KA and the 6 Hz paradigms are particularly relevant since these approaches model limbic seizures, which are the most commonly observed seizure type in patients with SCN3A mutations, including the patient with the L247P mutation (Barton et al., 2001; Holland et al., 2008; Vanoye et al., 2014). Taken together, these clinical and experimental findings suggest a role for SCN3A in the development of generalized and partial epilepsy.

While the Scn3a^{Hyp/Hyp} mutant did not express the L247P mutation identified in the patient, the observation of increased seizure susceptibility in the mutants provides support for the association between reduced SCN3A activity and increased seizure susceptibility. Although we did not observe spontaneous seizures in the Scn3a mice, we cannot exclude the possibility of infrequent seizures that were not captured during the periods of EEG analysis. It is noteworthy that two of the six Scn3a^{Hyp/Hyp} mice fitted with cortical electrodes exhibited brief, seizure-like behaviors, including rearing and falling. However, these behaviors did not correspond with electrographic seizure activity. Furthermore, we cannot exclude the possibility that the spontaneous seizures in the patient are the result of the toxic accumulation of mutant Na_v1.3 protein in the cells due to defective trafficking.

One general caveat of mouse models is that gene expression patterns can differ from humans. SCN3A is highly expressed during early development in humans and rodents, with expression declining into adulthood (Black et al., 1994; Chen et al., 2000; Felts et al., 1997; Whitaker et al., 2001). However, the relative reduction in adult Scn3a levels appears to be greater in the mouse. Nevertheless, a number of studies have revealed that Scn3a expression
is still detectable in certain brain regions, including the hippocampus and cortex, during adulthood (Beckh et al., 1989; Furuyama et al., 1993; Lindia and Abbadie, 2003). The observation of increased seizure susceptibility in Scn3α+/Hyp mutants suggest that Scn3α is still functionally important in the adult mouse. However, it is also possible that reduced Scn3α during early development results in long-term alterations in neuronal excitability or cortical organization. Future studies will investigate these possibilities.

4.3. A putative role for Scn3α in motor function and coordination

Scn3α+/Hyp mice exhibited reduced locomotor activity, suggesting hypoactivity, and decreased latency to fall from a rotarod. Interestingly, average latencies to fall from the rotarod were not significantly different between the genotypes during the initial trials; however, the performance of the mutants did not improve over time, indicating a deficit in motor learning. Poor rotarod performance suggests dysfunction of the cerebellum, since this brain region plays a crucial role in movement, motor coordination, and motor learning (Reeber et al., 2013). Studies in both rat and human have identified SCN3A expression in the granule, molecular, and deep cerebellar layers of the cerebellum, suggesting that SCN3A is expressed in excitatory granule cells as well as inhibitory cell types in the molecular layer. (Furuyama et al., 1993; Lindia and Abbadie, 2003; Whitaker et al., 2000; Whitaker et al., 2001). The patient with mutation L247P was unable to sit without support or walk at two years of age, suggesting a deficit in motor function. Additionally, the patient exhibits hypotonia, or low muscle tone, which can be partially attributed to cerebellar dysfunction (Koziol and Barker, 2013). Taken together, these results suggest a role for Scn3α in cerebellum-regulated motor function.

5. Conclusions

We report the identification of the novel de novo variant SCN3A-L247P in a patient with childhood epilepsy. SCN3A-L247P was demonstrated to cause a defect in trafficking, which would be predicted to functionally reduce SCN3A activity. Consistent with the clinical observations, Scn3α+/Hyp mice display increased seizure susceptibility, hypoactivity, and impaired motor learning. These observations support a role for SCN3A loss of function mutations, whether by reduced protein expression or defective trafficking, in epileptogenesis.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This work was supported by NIH grants to J.A.K. (NS053792) and A.E. (NS072221 and NS090319). The authors would like to thank the NHLBI GO Exome Sequencing Project and its ongoing studies which produced and provided exome variant calls for comparison: the Lung GO Sequencing Project (HL-102923), the WHI Sequencing Project (HL-102924), the Broad GO Sequencing Project (HL-102925), the Seattle GO Sequencing Project (HL-102926) and the Heart GO Sequencing Project (HL-103010). The authors would like to thank the Exome Aggregation Consortium and the groups that provided exome variant data for comparison. A full list of contributing groups can be found at http://exac.broadinstitute.org/about. We thank the patient and her family for their cooperation. We also thank the Emory Rodent Behavioral core for performing the locomotor activity task. Imaging work was performed at the Northwestern University Center for Advanced Microscopy generously supported by...
CCSG P30 CA060553 awarded to the Robert H. Lurie Comprehensive Cancer Center. Imaging was performed with a CRI Nuance spectral camera purchased with support from the Avon Foundation to Charles Cleveinger.

References


Highlights

- A de novo SCN3A mutation, L247P, was identified in a patient with focal epilepsy.
- SCN3A L247P mutation reduces cell surface expression of SCN3A.
- A hypomorphic Scn3a allele (Scn3a^{+/-Hyp}) increases seizure susceptibility in mice.
- Scn3a^{+/-Hyp} mutants exhibit impaired motor behavior and motor learning.
SCN3A-L247P is a trafficking deficient mutant. (A) Predicted transmembrane topology of Na\textsubscript{v}1.3 showing the location of the L247P variant characterized in this study. The S4 segments are shown in black with plus (+) signs and the grey rectangle behind the depiction represents the plasma membrane. (B) Multiple alignment of human homologs and species orthologs of Na\textsubscript{v}1.3 (Clustal Omega; (Sievers et al., 2011)). The variant amino acid L247P (shaded) is contained within a region of strong evolutionary conservation. (C) Average sodium current traces for SCN3A-WT and SCN3A-L247P co-expressed with β1 and β2 in a heterologous expression system (tsA201 cells). (D) Average current density-voltage relationships are shown for whole-cell currents tsA201 cells transiently co-expressing β1 and β2 with SCN3A-WT or SCN3A-L247P incubated at 37°C or 28°C for 24 hours prior to recording. (E) Total and surface protein were detected with anti-pan VGSC α subunit antibody or anti-transferrin receptor antibody as indicated. The WT SCN3A protein traffics normally to the cell surface, whereas trafficking of SCN3A L247P to the cell surface is significantly impaired.
Fig. 2.
Scn3a expression is reduced in Scn3a^{+/Hyp} mice. (A) Scn3a mRNA expression is reduced by approximately 70\% (p < 0.0001) and nearly 100\% (p < 0.0001) in Scn3a^{+/Hyp} and Scn3a^{Hyp/Hyp} mice respectively. mRNA expression, quantified from real-time PCR analysis, was normalized to β-actin. Expression values for each genotype are relative to WT levels. n = 4 (WT), 5 (Scn3a^{+/Hyp}), 3 (Scn3a^{Hyp/Hyp}). (B) Scn3a protein expression, quantified from Western blot analysis, is reduced by approximately 35\% (p < 0.05) and 60\% (p < 0.001) in membrane-enriched whole brain homogenate from Scn3a^{+/Hyp} and Scn3a^{Hyp/Hyp} mice, respectively. Optical density (OD) expression values are relative to WT and normalized to α-tubulin; n = 5 (WT), 6 (Scn3a^{+/Hyp}), 4 (Scn3a^{Hyp/Hyp}). Protein results represent the means of triplicate values for each genotype. *p < 0.05, *** < 0.001, ****p < 0.0001; One-way ANOVA. Error bars indicate SEM.
Fig. 3.
Expression of Scn1a, Scn2a, and Scn8a in Scn3a+/Hyp mice. (A) Scn1a, (B) Scn2a, and (C) Scn8a mRNA expression, quantified from real-time PCR analysis, is significantly reduced in whole brain samples from P1 Scn3aHyp/Hyp mice. n = 4 (WT), 5 (Scn3a+/Hyp), 3 (Scn3aHyp/Hyp). Expression values are relative to WT and normalized to β-actin. *p < 0.05, One-way ANOVA. Error bars indicate SEM.
Fig. 4. *Scn3a*+/Hyp mice do not exhibit increased susceptibility to hyperthermia-induced seizures. Seizure generation in response to increasing body temperature was comparable between *Scn3a*+/Hyp mutants (n = 12) and WT littermates (n = 13). Log-Rank Survival Test.
Fig. 5. *Scn3a*+/Hyp mice exhibit increased susceptibility to 6 Hz psychomotor seizures. (A) The CC50 is significantly lower for *Scn3a*+/Hyp mice compared with WT littermates; n = 10/ genotype. (B) The difference in the average Racine score between *Scn3a*+/Hyp mutants and WT littermates was not statistically significant for any current. Mann-Whitney Rank Sum test. Error bars indicate SEM.
Fig. 6. *Scn3a*+/Hyp mice exhibit increased susceptibility to fluoroethyl-induced seizures. (A) Male *Scn3a*+/Hyp mutants exhibit significantly shorter latencies to the first MJ and HLE when compared to WT littermates. (B) Female *Scn3a*+/Hyp female mice have significantly shorter latencies to all three seizure components when compared to WT; male n = 33 (WT), 29 (*Scn3a*+/Hyp); female n = 32 (WT), 29 (*Scn3a*+/Hyp). **p < 0.01, ***p < 0.001, Two-tailed Student’s t-test. Error bars indicate SEM.
Fig. 7.

Scn3a+/Hyp mice exhibit increased susceptibility to KA-induced seizures. (A) Following the administration of KA, Scn3a+/Hyp mutants (n = 8) exhibited significantly more severe seizure phenotypes when compared to WT littermates (n = 5). *p < 0.05; Two-way repeated measures ANOVA. (B) Average latency to the first electrographic seizure was shorter in Scn3a+/Hyp mutants. *p < 0.05, Two-tailed Student’s t-test. (C) A representative EEG recording during a KA-induced seizure in a mutant mouse. Seizure onset and termination are indicated within brackets. EEG montage: Cortical EEG 1, Cortical EEG 2, Cortical EEG 3, and Cortical EEG 4 – cortical electrodes. EMG – muscle electrodes. All cortical electrodes and EMG referenced to a second EMG electrode. Error bars indicate SEM.
Fig. 8. 
Scn3a<sup>+/Hyp</sup> mice exhibit deficits in motor behavior. (A) Scn3a<sup>+/Hyp</sup> mice (n = 8) traveled significantly less than WT (n = 8) during the first dark phase (hours 6.5–9.5) and the second dark phase (hour 31.5–32.0). Inset shows locomotor activity during hours 6.5–9.5. **p < 0.01, ***p < 0.001, ****p < 0.0001; Two-way repeated measures ANOVA (Genotype × Time). White and black bars below the X-axis represent the light and dark periods, respectively. (B) Latency to fall from the rotarod was significantly shorter for Scn3a<sup>+/Hyp</sup> mutants (n = 11) when compared to WT littermates (n = 9) from trial 6 (Day 2) to the last trial (trial 9) on Day 3. *p < 0.05, **p < 0.01, Two-way repeated measures ANOVA (Genotype × Time). Error bars indicate SEM.